Buck Institute President and CEO Brian Kennedy, PhD, discusses research from his lab that shows the FDA-approved drug rapamycin is an effective treatment in mouse models of inherited heart disease and rare muscular dystrophies. The study, published in the July 25, 2012 on-line edition of Science Translational Medicine, focuses on mutations in the LMNA gene, which leads to dilated cardiomyopathy, Emery-Dreifuss muscular dystrophy, and limb-girdle muscular dystrophy. There are currently no effective treatments for the diseases. The familial form of dilated cardiomyopathy often leads to sudden heart failure and death when those affected reach their 40s and 50s.

Loading more stuff…

Hmm…it looks like things are taking a while to load. Try again?

Loading videos…